

INTERNATIONAL
STANDARD

ISO
22679

First edition
2021-11

**Cardiovascular implants —
Transcatheter cardiac occluders**

iTeh Standards
(<https://standards.iteh.ai>)
Document Preview

[ISO 22679:2021](https://standards.iteh.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38fff3a238d6/iso-22679-2021)

<https://standards.iteh.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38fff3a238d6/iso-22679-2021>



Reference number
ISO 22679:2021(E)

© ISO 2021

iTeh Standards
(<https://standards.itih.ai>)
Document Preview

[ISO 22679:2021](https://standards.itih.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38fff3a238d6/iso-22679-2021)

<https://standards.itih.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38fff3a238d6/iso-22679-2021>



COPYRIGHT PROTECTED DOCUMENT

© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

	Page
Foreword.....	v
Introduction.....	vi
1 Scope.....	1
2 Normative references.....	1
3 Terms and definitions.....	2
4 Abbreviations.....	6
5 Fundamental requirements.....	7
5.1 General.....	7
5.2 Risk management.....	7
6 Device description.....	8
6.1 General.....	8
6.2 Intended use.....	8
6.3 Design inputs.....	8
6.3.1 Operational principles and specifications.....	8
6.3.2 Functional, performance and safety requirements.....	8
6.3.3 Implant procedure: Device and usability requirements.....	9
6.3.4 Packaging, labelling and sterilization.....	10
6.4 Design outputs.....	10
6.5 Design transfer (manufacturing verification or validation).....	10
7 Design verification and validation.....	10
7.1 General requirements.....	10
7.2 In vitro assessment.....	11
7.2.1 General.....	11
7.2.2 Test conditions, sample selection and reporting requirements.....	11
7.2.3 Material property assessment.....	12
7.2.4 Structural performance assessment.....	13
7.2.5 Component corrosion assessment.....	14
7.2.6 Visibility.....	14
7.2.7 Visual inspection.....	15
7.2.8 Dimensional verification.....	15
7.2.9 Device MRI compatibility.....	15
7.2.10 Simulated use assessment.....	15
7.2.11 Usability engineering process.....	15
7.2.12 Design- or procedure-specific testing.....	15
7.3 Preclinical in vivo evaluation.....	15
7.3.1 General.....	15
7.3.2 Overall requirements.....	15
7.3.3 Methods.....	17
7.3.4 Test report.....	18
7.4 Clinical investigations.....	19
7.4.1 General.....	19
7.4.2 Study considerations.....	20
7.4.3 Imaging assessment.....	21
7.4.4 Study design.....	21
7.4.5 Explant analysis.....	21
7.4.6 Pilot study considerations.....	22
7.4.7 Study endpoints.....	22
7.4.8 Ethical considerations.....	22
7.4.9 Pivotal studies: Distribution of subjects and investigators.....	23
7.4.10 Site qualification and training requirements.....	23
7.4.11 Study population.....	23
7.4.12 Statistical considerations.....	24

7.4.13	Sample size	25
7.4.14	Duration of study	25
7.4.15	Patient selection criteria	25
7.4.16	Clinical data requirements	26
Annex A	(informative) Rationale for the provisions of this document	31
Annex B	(informative) Transcatheter cardiac occluder hazard analysis example	34
Annex C	(normative) Packaging	36
Annex D	(normative) Product labels and instructions for use	37
Annex E	(normative) Sterilization	38
Annex F	(informative) Corrosion assessment	39
Annex G	(informative) In vitro test guidelines for paediatric devices	42
Annex H	(informative) Fatigue and durability assessment	44
Annex I	(normative) Adverse event classification during clinical investigation	50
Annex J	(informative) Imaging protocol	55
Annex K	(informative) Clinical investigation endpoints for transcatheter cardiac occluders: Suggestions for endpoints and their timing	56
Annex L	(informative) Examples of design specific testing	59
Annex M	(informative) Guidelines for delivery system design evaluation	61
Annex N	(normative) Preclinical in vivo evaluation	63
Annex O	(informative) In vitro test pressure guidelines	66
Annex P	(informative) Training for physicians and support staff	68
Bibliography	69

[ISO 22679:2021](https://standards.iteh.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38fff3a238d6/iso-22679-2021)

<https://standards.iteh.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38fff3a238d6/iso-22679-2021>

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

<https://standards.iteh.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38fff3a238d6/iso-22679-2021>

Introduction

The field of transcatheter cardiac occluders has advanced and expanded significantly in recent years. Therefore, a group of engineers, scientists, and clinicians, experts well aware of the problems associated with transcatheter cardiac occluder devices and their development, has prepared this document. This document deals with those areas that will help ensure adequate mitigation of device-associated risks for patients and other users of the device, facilitate quality assurance, and help ensure that the device will be provided in a convenient and usable form. This document emphasizes the need to specify and report types of in vitro testing, preclinical in vivo, and clinical evaluations. It describes the requirements for labels and packaging of the device. The in vitro, preclinical in vivo, and clinical evaluations described in this document are intended to help establish safety and performance of a transcatheter cardiac occluder.

This document outlines an approach for minimizing adverse events from the implantation of a transcatheter cardiac occluder through risk management. The selection of appropriate verification or validation tests and methods are derived from the risk assessment and design input requirements. The tests include those to assess the physical, mechanical, chemical, and biological properties of transcatheter cardiac occluders and of their materials and components. The tests also include those for preclinical in vivo evaluation and clinical evaluation of the transcatheter cardiac occluders.

iTeh Standards (<https://standards.iteh.ai>) Document Preview

[ISO 22679:2021](https://standards.iteh.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38ff3a238d6/iso-22679-2021)

<https://standards.iteh.ai/catalog/standards/iso/263e7e35-ec4e-4d4e-a519-38ff3a238d6/iso-22679-2021>

Cardiovascular implants — Transcatheter cardiac occluders

1 Scope

This document specifies important in vitro tests including functional and durability characteristics of transcatheter cardiac occluders, and their delivery systems and accessories. This document does not specify exact test methods for functional and durability testing, but it offers requirements and recommendations for performance tests of the cardiac occluder system.

Surgical occluders have been omitted from the scope of this document given their significant differences in device geometry, materials, implantation methods, and test methods as compared to transcatheter cardiac occluders.

This document is applicable to all intracardiac occluders intended for transcatheter implantation in humans (e.g. atrial septal occluder, ventricular septal occluder, patent foramen ovale occluder, left atrial appendage occluder, and paravalvular leak occluders). This document does not cover non-cardiac occluders, but elements of this document can be applicable to patent ductus arteriosus occluders.

The following devices and components are outside the scope of this document: surgical devices, cardiac shunt devices, atrial flow regulators, active components (such as sensors), or degradable or animal tissue components.

This document is applicable to both newly developed and modified cardiac occluders, their accessory devices, packaging, and labelling.

This document defines operational conditions and performance requirements for cardiac occluders where either adequate scientific or clinical evidence, or both, exists for their justification.

NOTE At the time of this document, it is impossible to take all future and emerging technologies into consideration. The cardiac occluder systems based on these new technologies can benefit from evaluation based on the basic requirements of this document. Testing beyond the scope of this document can also be necessary in order to verify and validate these cardiac occluder systems.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10555-1, *Intravascular catheters — Sterile and single-use catheters — Part 1: General requirements*

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 11070, *Sterile single-use intravascular introducers, dilators and guidewires*

ISO 11135-1, *Sterilization of health care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 11137-1, *Sterilization of health care products — Radiation — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO 11137-2, *Sterilization of health care products — Radiation — Part 2: Establishing the sterilization dose*